Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement

Executive Summary

Legal agreement with FDA allowing communication about off-label Vascepa use is not limited by audience, speaker or setting, attorneys say.

You may also be interested in...



FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research

Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.

When Expanded Access Also Means Off-Label Use, US FDA May Need New Policy

For now, FDA is using a case-by-case approach for reviewing and approving expanded access applications asking for off-label uses.

Amarin Says REDUCE-IT Results Are Off Limits To Omega-3 Supplement Claims

REDUCE-IT results are limited to Amarin's Vascepa "and cannot be extrapolated to omega-3 products that are materially different based on, for example, composition, dosage, and regulatory status," pharma firm says in complaints against Coromega and Omax. Amarin seeks to stifle the omega-3 supplement firms despite First Amendment argument it made in successful litigation against FDA to make truthful statements about its products even though the information is not approved by the agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel